CASI Pharmaceuticals, Inc., incorporated on September 18, 1991, is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. The Company operates through the development of targeted therapeutics primarily for the treatment of cancer segment. The Company's product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, the United States Food and Drug Administration (FDA) approved drugs in-licensed from Spectrum Pharmaceuticals, Inc., and early-stage candidates in preclinical development. The Company's pipeline also includes 2ME2 (2-methoxyestradial). The Company's primary research and development focuses on oncology therapeutics.
ENMD-2076
The Company's ENMD-2076 is an orally active, Aurora A/angiogenic kinase inhibitor with a kinase selectivity profile and multiple mechanisms of action. It has shown anti-angiogenic and anti-proliferative properties in multiple preclinical and clinical cancer studies. ENMD-2076 has shown to inhibit angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division) and are over-expressed in human cancers. ENMD-2076 also targets the vascular endothelial growth factor receptors (VEGFR), FMS-like tyrosine kinase-3 (Flt-3) and fibroblast growth factor receptor 3 (FGFR3) kinases, which has shown to play important roles in the pathology of several cancers. ENMD-2076 has completed Phase I clinical trial in various different solid tumor cancers, including ovarian, breast, liver, renal and sarcoma, as well as in leukemia, and multiple myeloma, and has also completed a Phase II clinical trial in advanced ovarian cancer. It has initiated multiple Phase II studies of ENMD-2076 in triple-negative breast cancer (TNBC), advanced/metastatic soft tissue sarcoma (STS) and in advanced ovarian clear cell carcinomas (OCCC) in North America. ENMD-2076 has received orphan drug designation from the FDA for the treatment of ovarian cancer, multiple myeloma, acute myeloid leukemia and hepatocellular carcinoma (HCC).
MARQIBO
The Company's Marqibo is a sphingomyelin/cholesterol liposome-encapsulated, formulation of vincristine sulfate, a microtubule inhibitor. Marqibo is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or having disease that has progressed following two or more anti-leukemia therapies.
ZEVALIN
The Company's ZEVALIN (ibritumomab tiuxetan) injection for intravenous use is a CD20-directed radiotherapeutic antibody. It is indicated for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). ZEVALIN is also indicated for the treatment of patients with previously untreated follicular NHL having achieved a partial or complete response to first-line chemotherapy. ZEVALIN therapeutic regimen consists of two components: rituximab and Yttrium-90 (Y-90) radiolabeled ZEVALIN for therapy. ZEVALIN builds on the combined effect of a targeted biologic monoclonal antibody augmented with the therapeutic effects of a beta-emitting radioisotope.
EVOMELA
The Company's EVOMELA is a new intravenous formulation of melphalan being investigated by Spectrum in the multiple myeloma transplant setting. The formulation avoids the use of propylene glycol, which is used as a co-solvent in the current formulation of melphalan and has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. EVOMELA (melphalan) is indicated for Injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
2ME2
The Company's 2ME2 (2-methoxyestradiol) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties. The inhibition of angiogenesis is an approach to the treatment of both cancer and autoimmune diseases, such as rheumatoid arthritis. 2ME2 is a single agent in rheumatoid arthritis based on its antiangiogenic, anti-inflammatory and anti-osteoclastic (bone resorption) properties. 2ME2 has also demonstrated positive preclinical results for multiple sclerosis.
9620 Medical Center Dr Ste 300
The company trades on NASDAQ exchange. The company headquarter is located in Maryland, MD. The company was established in the 1991.| Ticker | CASI |
| Long Name | CASI Pharmaceuticals, Inc. |
| Short Name | CASI Pharma |